Bone marrow transplantation as part of «Help3 Project» in Tanzania

Cornelio Uderzo, MD

Pediatric DPT, University of Milan (Italy) S.Gerardo hospital (Monza), MBBM Foundation cornelio.uderzo@help3.it

April 1st- 2022, MMH (Zanzibar)



Help3 2015-2022: activities

- SINCE 2015 : focus on «sickle cell disease»
- four SCD "outpatients" activated in 4 Hospitals :

TANZANIA: BMC-Mwanza, St.Gemma H-Dodoma, Mnazi Mmoja H-Zanzibar

UGANDA: Lacor hospital

- Donation of Hydroxyurea for the treatment of 800 SCD children
- Donation of "data base" SCD oriented
- Donation of three "Electrophoresis of Hb" instruments
- > Italian hematologysts available every day for consultation
- SINCE 2019 : focus on «Bone marrow transplantation»
- Collaboration with BMH (Dodoma) toward the Start up of Haematologic and BMT Unit for the diagnosis and treatment of SCD and other hematologic diseases

SCD in Tanzania up to 2022

- SCD birth prevalence /year:
 6-10 per 1000 births (around 20.000)
- SCD children MR/year = 10.500 (J. Makani)
- U5-MR for SCD = 50 to 90%
- <u>U5-MR for Malaria = 10 % (WHO data)</u>

Five years interactivity at St.G.H, Dodoma

Training at the beginning...



Sickle cell clinic:

450 SCD treated children



Five years interactivity at MMH

MNAZI MMOJA HOSPITAL (ZZ) :

200 SCD treated children





HELP3 Project: our targets

- to decrease the SCD "U5-MR" and to improve the SCD survival and QOL, decreasing also the "social costs"
- to create a fruitful advocacy within National and International NGOs in favour of Tanzania
- to cure definitively by standard therapy and BMT both childhood SCD and other blood diseases

Estimated yearly Incidence of childhood leukemia and lymphoma in "Tanzania"

NEW LEUKEMIAS/YEAR

2000 patients (1 to 18 yrs)

- ❖ 700 in the areas of
- Mwanza
- Dodoma
- DAR
- Zanzibar

NEW LYMPHOMAS/YEAR

2500 patients (1 to 18 yrs)

- * 800 in the areas of
- Mwanza
- Dodoma
- DAR
- Zanzibar

HELP3 ongoing strategy



Maintenance of collaboration, training and echonomical support to St.G.H and MMH



Since 2019 at BMH (Dodoma)

**At distance training (45teleconferences)

** Stages in Italy for Tanzanian nurses and medical staff of BMH (2021-2002)

** «Start up» of an hematologic and BMT center at Benjamin Mkapa Hospital (Dodoma) on 2022

Direct beneficiaries up to now:

- ❖ SCD patients (650)
- Nurses/medical staff in the hospitals (20)
- Parents and relatives of the SCD patients (1250)
- Doctors on the districts (10)

WHY <u>BMT CENTERS for</u> childhood hematological diseases in "TANZANIA"?

- > SITUATION in AFRICA up to 2020
- **11 BMT centers in Africa** for 1 milliard of people (<u>1 in Nigeria, 6 in South Africa, 1 in Tunisia, 1 in Morocco, 1 in Egypt, <u>1 in Tanzania</u>)</u>
- BMT centers needed in <u>"sub-saharan area"</u>: 15 (??)
- BMT centers needed in TANZANIA: 3-4 (??)
- ➤ Probable costs for building up a Pediatric BMT Unit in subequatorial area (excluding personnel) : 350.000 \$
- Probable costs for 1 allogeneic BMT in Tanzania: 15.000 \$
- Probable costs for 1 allogeneic BMT overseas: 40.000 to 150.000 \$
- Probable costs of 5 to 7 years of "SCD" standard treatment:
 10.000 \$

Bone marrow transplantation (BMT) : definitions

- ** Bone Marrow Transplantation is a modern treatment consisting on the substitution of "patient hematopoietic stem cells" with "HLA compatible donor" stem cells
- ** BMT donor is generally a family HLA identical donor
- ** The new bone marrow is harvested in an operating room and infused intravenously to the patient previously conditioned
- ** **BMT** is applied on those patients who are "poor responders" to standard treatment
- **BMT is the most complex organ transplant due to the multiple complications (rejection...) if not done by a very expert transplant team and in an adequate structure

BMT INDICATIONS in children affected with:

Malignancies:

- * Leukemia
- * Lymphoma
- *** MDSyndrome**
- * Solid tumors

Non malignancies:

- **★Sickle cell Disease (SCD)**
- * Severe aplastic anemia
- ***** Immunodeficiency
- Inherited metabolism disorders
- * Autoimmune diseases

WHY BMT for "SCD" in childhood?

- is the only "curative treatment" for SCD since 20 years in "high income countries" with 95% of "cure rate" and no recurrence of clinical "vaso-occlusive crisis" and no new ischemic lesions after successfull transplant
- High "quality of life" after BMT

WHY BMT for malignant diseases in childhood?

- <u>High "cure rate"</u> (60-70%) in patients with "resistant diseases" after standard chemotherapy
- > BMT success in a large series of patients all over the world since last 2 decades
- BMT, Innovative treatment, is feasible today also in "developing countries" including "Subsaharan area"

S. Gerardo University hospital (Monza-ITALY) **BMT Pediatric Unit**





- First alloBMT: June 1985
- 36 yrs of experience
- \triangleright Total n° of BMTs = 850
- ► 75% AlloBMTs and 25% AutoBMTs
- ➤ Malignancies : 70%
- ➤ Non-Malignancies : 30%
- > Total Post BMT TRM: 10%
- ➤ Alive/well at median Fup of 10 yrs: 64%
- **➢ Global Medicine and Cooperation**
- International Scientific research

Bone marrow harvesting



Bone marrow infusion







Cured patients at S.Gerardo Hospital winners on Wordl transplant games





London, Canada – July 2006-2010

Autologous BMT in AML : longterm QOL

- > A.Z., Male , 13 yrs old at diagnosis
- ** 1998 : Diagnosis of AML M2
- ** CR1 obtained and maintained for 3 months
- ** 1999 : receiving an <u>AutoBMT</u> in first CR after BU-CY
- ** 2010-2014 : Olimpic Games champion
- ** **2014**: owner of a riding school
- ** 2015 : married
- ** 2021: cured with excellent life

satisfaction



BMH: «core» of the Help3 project since 2019



With proper «task force»





Successfull BMT program at BMH

depends from:

- will-power and commitment of «doctors and nurses»
- a competent local «BMT team» in a specialized Hospital
- a continued "training" and «updating»
- a comprehensive financial support since the beginning!
- assuring the maintenance of the BMT activity along the years

Our dream is to «cure» the childhood hematological diseases <u>in Tanzania as well as</u> it happens in HICs





CONCLUSION 1

- <u>In most developing countries</u>, a HSCT program must compete for allocation of limited funds with other priorities for basic health care services, such as food, sanitation, immunization, population control, and communicable disease prevention.
- Nonetheless, <u>developing countries</u> should have the expertise to offer state-of-the-art treatments, including HSCT, to enable treatment locally at a much lower cost than abroad.

CONCLUSION 2

As new programs plan,
 Tertiary Care Centers in
 LICS should consider
 establishing a relationship early
 with an experienced HSCT center
 within the region or remotely (eg,
 telemedicine or a "twinning"
 partnership arrangement) to
 provide experienced advice in the
 context of HSCT procedures

 Right to health is mandatory for children all over the world



CONCLUSION 3

The development of curative treatment for children with cancer is a benchmark for medical progress and such treatment <u>must not be sequestered within the borders of few countries</u>

Raul C. Ribeiro and Ching Hon Pui NEJM may 2005

Asante Sana





BMT BASAL REQUIREMENTS

OUTPATIENT FACILITIES (with air conditioning)

STAFF: 2 doctors + 4 Medical doctors; 8 (10) nurses;1 chief of nurses

BASAL STRUCTURE:


- large common room with 10 beds for transfusions, infusions + 4 bathrooms
- 2 rooms for invasive and non-invasive procedures (BM aspiration, lumbar puncture......
- 1 Nurses station for preparation of infusions and any kind of procedure (+ Internet/Intranet)
- 1 Doctors station with Internet/Intranet


OUTPATIENT FACILITIES (with air conditioning


SUPPORT AEREA:

- One protective cabinet
- Storage room (for drugs, (scales, monitors......)
- 1 "Play/rest room" for patients and/or parents
- 1 rest room and 2 bathrooms for the personnel and parents
- 1 room for "social worker and/or psycologyst

Comparative effects of TP, HU and BMT on frequency of Hosp, VOC, ACS in 111 **SCD-patients**







Arnaud et al CHI-Creteil, ASH